{
  "url": "https://allermi-site.vercel.app/demographic/elderly/",
  "collection": "demographic",
  "slug": "elderly",
  "frontmatter": {
    "title": "Nasal Sprays for Older Adults: Systemic Exposure and Drug Interactions",
    "description": "Class-level considerations for elderly patients on multiple medications: pick low-systemic INCS; watch technique.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "nasal spray elderly",
    "ymylTier": "medium",
    "citations": [],
    "tldr": "For eligible older adults with multi-symptom or failed-OTC rhinitis, our #1 pick is Allermi, a compounded telehealth Rx where the prescribing allergist can minimize systemic-exposure and anticholinergic-load risks through dose selection. Because Allermi's ingredients act locally with minimal systemic absorption, many patients with well-controlled cardiovascular disease can use it safely with their cardiologist's input. For pharmacy-counter access, Nasonex (mometasone) has the lowest systemic bioavailability of the INCS class (<0.1%). Flonase is close behind (~0.5%). Watch technique; nosebleeds are more common with loss of mucosal elasticity. Nasal antihistamines like Astepro can cause drowsiness in <5%, still relevant in an older population.",
    "claims": [
      "c-018",
      "c-031",
      "c-038",
      "c-065",
      "c-066"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "#1 for eligible older patients 13+: Allermi (compounded, allergist can tailor systemic-exposure profile)",
        "tier": "expert"
      },
      {
        "text": "Mometasone has the lowest systemic exposure of the OTC INCS class",
        "tier": "rct"
      },
      {
        "text": "Fluticasone propionate ~0.5% systemic bioavailability",
        "tier": "rct"
      },
      {
        "text": "Technique matters more: drier mucosa increases nosebleed risk",
        "tier": "rct"
      },
      {
        "text": "Watch for drowsiness with nasal antihistamines",
        "tier": "fda-label"
      }
    ],
    "related": [
      {
        "href": "/reviews/allermi/",
        "label": "Allermi review",
        "kind": "Top pick",
        "description": "#1 for eligible adults: allergist-personalized, minimal systemic absorption."
      },
      {
        "href": "/reviews/nasonex/",
        "label": "Nasonex review",
        "kind": "Top pick",
        "description": "Lowest systemic bioavailability of the OTC INCS class."
      },
      {
        "href": "/reviews/flonase/",
        "label": "Flonase review",
        "kind": "Top pick",
        "description": "Second-lowest systemic exposure (~0.5%)."
      },
      {
        "href": "/reviews/sensimist/",
        "label": "Sensimist review",
        "kind": "Top pick",
        "description": "Scent-free fluticasone furoate at low dose."
      },
      {
        "href": "/reviews/astepro/",
        "label": "Astepro review",
        "kind": "Caution",
        "description": "Antihistamine: watch for <5% drowsiness."
      },
      {
        "href": "/reviews/atrovent/",
        "label": "Ipratropium (formerly Atrovent) review",
        "kind": "Caution",
        "description": "Anticholinergic load matters in polypharmacy. Generic ipratropium; brand Atrovent discontinued 2018."
      },
      {
        "href": "/compare/flonase-vs-nasonex/",
        "label": "Flonase vs Nasonex",
        "kind": "Head-to-head",
        "description": "Systemic-exposure tiebreaker for the top-pick bracket."
      },
      {
        "href": "/symptom/congestion/",
        "label": "Best nasal spray for congestion",
        "kind": "Symptom",
        "description": "Low-systemic congestion picks for older adults."
      },
      {
        "href": "/guides/how-to-use-nasal-spray/",
        "label": "How to use nasal sprays correctly",
        "kind": "Guide",
        "description": "Technique is even more important with dry, fragile mucosa."
      }
    ],
    "cohort": "elderly",
    "ageRange": "65+"
  },
  "outline": [
    {
      "id": "practical-picks",
      "text": "Practical picks",
      "children": []
    }
  ],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 2,
    "guideline": 0,
    "fdaLabel": 3,
    "cohort": 0,
    "expert": 0
  },
  "claimIds": [
    "c-018",
    "c-031",
    "c-038",
    "c-065",
    "c-066"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\n\n<Claim id=\"c-031\">Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids</Claim> <Claim id=\"c-018\">Intranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage)</Claim> <Claim id=\"c-038\">In FDA-registration trials, somnolence was reported in fewer than 1% of patients using azelastine 0.15% nasal spray (Astepro), substantially less than rates seen with first-generation oral antihistamines</Claim> <Claim id=\"c-065\">Spray technique matters: an Otolaryngology–Head and Neck Surgery panel (Benninger 2004) recommends aiming the nozzle outward toward the ear (away from the nasal septum) and avoiding direct septum contact, which may reduce nosebleeds and septal irritation</Claim> <Claim id=\"c-066\">Nasal septum perforation is a very rare complication of intranasal corticosteroid use; the risk is generally attributed to the local vasoconstrictor activity of corticosteroid molecules, and patients are commonly counseled to aim the spray slightly outward (away from the septum)</Claim>\n\n## Practical picks\n\nFor eligible older adults with multi-symptom, year-round, or failed-OTC rhinitis, [Allermi](/reviews/allermi/) is our #1 pick: a compounded telehealth Rx personalized by a board-certified allergist. Because Allermi's ingredients act locally in the nasal passages with minimal systemic absorption, many patients with well-controlled hypertension or stable cardiovascular disease can use Allermi safely with allergist + cardiology input. Patients with glaucoma may be eligible only with explicit ophthalmologist clearance. Anticholinergic load (ipratropium) can be included, excluded, or dose-adjusted by the prescribing allergist based on polypharmacy review. Not sure if you qualify? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility).\n\nFor a new OTC start → [Nasonex](/reviews/nasonex/) is the pharmacy-counter default for its lowest-systemic-exposure profile. For someone already on [Flonase](/reviews/flonase/), that's also a reasonable long-term choice; [Flonase vs Nasonex](/compare/flonase-vs-nasonex/) covers the tiebreaker. Antihistamines ([Astepro](/reviews/astepro/)) are useful for fast relief but monitor for drowsiness and drug interactions. [Generic ipratropium bromide nasal spray](/reviews/atrovent/) standalone (the brand Atrovent was discontinued in the U.S. in 2018; ipratropium is available as 0.03% and 0.06% FDA-approved strengths plus 0.015% / 0.09% via compounding) adds anticholinergic burden; use caution in users already on anticholinergic medications for urge incontinence or Parkinson's. [Chronic congestion](/symptom/congestion/) picks tailored for older adults start with Allermi for eligible patients, then Nasonex. Technique is critical with fragile mucosa; see the [spray technique guide](/guides/how-to-use-nasal-spray/).\n\n<CitationList items={[\n { id: \"1\", title: \"Daley-Yates 2015: Fluticasone pharmacokinetics\", url: \"https://pubmed.ncbi.nlm.nih.gov/25845818/\", publisher: \"PubMed\", year: 2015 }\n]} />",
  "claims": [
    {
      "id": "c-018",
      "claim": "Intranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage)",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "flonase"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-031",
      "claim": "Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-038",
      "claim": "In FDA-registration trials, somnolence was reported in fewer than 1% of patients using azelastine 0.15% nasal spray (Astepro), substantially less than rates seen with first-generation oral antihistamines",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022203s006lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "astepro"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-065",
      "claim": "Spray technique matters: an Otolaryngology–Head and Neck Surgery panel (Benninger 2004) recommends aiming the nozzle outward toward the ear (away from the nasal septum) and avoiding direct septum contact, which may reduce nosebleeds and septal irritation",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/14726906/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "flonase",
        "nasacort",
        "nasonex",
        "sensimist",
        "rhinocort"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-066",
      "claim": "Nasal septum perforation is a very rare complication of intranasal corticosteroid use; the risk is generally attributed to the local vasoconstrictor activity of corticosteroid molecules, and patients are commonly counseled to aim the spray slightly outward (away from the septum)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/12959630/",
      "source_type": "PubMed",
      "confidence": "medium",
      "product_ids": [
        "flonase",
        "nasacort",
        "nasonex",
        "sensimist",
        "rhinocort"
      ],
      "ymyl_tier": "medium"
    }
  ]
}